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Cannabidiol as a potential treatment for febrile 
infection‑related epilepsy syndrome (FIRES) 
in the acute and chronic phases
This study is a case series of seven children from five US 
hospitals. All of the children had the rare but devastating 
febrile infection-related epilepsy syndrome (FIRES). FIRES 
affect school age children and is characterized by a febrile 
illness followed by very frequent multi-focal seizures with 
refractory status epilepticus (acute phase). The chronic 
phase consists of pharmacoresistant epilepsy with signifi-
cant cognitive and behavioral effects. The etiology of FIRES 
is unknown and there is currently no effective treatment, 
although the ketogenic diet has shown some promise.
The children in this study had an extensive workup for 
other causes of new onset status epilepticus. They were 
given cannabidiol using an emergency or expanded access 
investigational new drug protocol. Two children started 
cannabidiol in the acute phase with the remainder starting 
the drug in the chronic phase. Before starting cannabidiol, 
the participants had trialed a median of seven anti-epileptic 
drugs, had been given steroids or intravenous immunoglobu-
lin and all but one of the children had been given a ketogenic 
or modified Atkins diet. Five of the participants had trials of 
multiple anesthetic agents. One participant was given 15 mg/
kg/day of cannabidiol, one was given 20 mg/kg/day with 
the remainder having the maximum dose of 25 mg/kg/day.
One of the two patients treated in the acute stage of 
FIRES died of multi-organ failure; the other had a cessa-
tion of their status epilepticus. In the remaining five patients 
treated in the chronic phase, there was a mean decrease in 
seizure frequency of 91% 4 weeks after and 65% 48 weeks 
after treatment when compared with pre-treatment seizure 
frequency.
Despite an increasing number of anti-epileptic drugs 
(AEDs), the proportion of drug-resistant cases of epilepsy 
has remained fairly static at around 30% and the search for 
new and improved AEDs continues. Cannabis has been used 
as a medical treatment for epilepsy for thousands of years; it 
contains many active compounds, the most important being 
tetrahydrocannabinol, which has psychoactive properties, 
and cannabidiol, which does not. Animal models and clinical 
data to date have suggested that cannabidiol is more useful 
in treating epilepsy; there is limited evidence that tetrahy-
drocannabinol has some pro-convulsant effects in animal 
models. The mechanism by which cannabidiol exerts its 
anti-convulsant properties is currently unclear.
This month’s journal club reviews three papers using 
cannabidiol for the treatment of epilepsy. The first paper 
describes a small case series where cannabidiol is used in 
a rare pediatric epilepsy syndrome, febrile infection-related 
epilepsy syndrome (FIRES); the second paper is a larger 
open label study of cannabidiol in a variety of refractory 
epilepsies and the third paper describes a randomized con-
trol trial of cannabidiol in Dravet syndrome.
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Comment. This was a small case series in a very rare epi-
lepsy syndrome and the usual caution needs to be exercised 
when interpreting these results. Despite this, the results seem 
to suggest that cannabidiol can be considered in FIRES as an 
additional therapy when conventional therapies have failed.
Gofshteyn JS et al (2017) J Child Neurol 32(1):35–40.
Cannabidiol in patients with treatment‑resistant 
epilepsy: an open‑label interventional trial
This is an open-label study series of children and young 
adults across eleven US epilepsy centers. Inclusion criteria 
were that the patients were aged between 1 and 30 years, 
had intractable childhood onset epilepsy, had four or more 
seizures with a motor component per month, and were on 
stable doses of antiepileptic drugs for at least a month before 
enrolment. Patients were given cannabidiol and doses were 
titrated to either 25 or 50 mg/kg/day. The primary endpoints 
were safety and tolerability of cannabidiol (safety analysis 
group) and median change in mean seizure frequency at 
12 weeks compared to baseline (efficacy analysis group). 
Parents and carers recorded seizure frequency using seizure 
diaries.
214 patients were recruited, 52 did not have 3 months 
of follow-up data, 11 dropped out before 12 weeks because 
of adverse effects, worsening seizures, or sudden death 
in epilepsy (1 patient). 162 patients were included in the 
safety analysis group. There were a variety of underlying 
severe epilepsies including Dravet syndrome (20%) and Len-
nox Gastaut syndrome (19%). A further 25 patients were 
excluded from the safety analysis group (mainly due to not 
having motor seizures) to leave 137 patients in the efficacy 
group.
Adverse events were reported in 80% of the safety group, 
these included somnolence (25%), decreased appetite (19%), 
diarrhea (19%), fatigue (13%), convulsions (11%), increased 
appetite (9%) and status epilepticus (8%). Serious adverse 
events were reported in 48 (30%) patients, including one 
death—a sudden unexpected death in epilepsy regarded as 
unrelated to study drug. Of these, 20 (12%) patients had 
severe adverse events thought to be possibly related to can-
nabidiol use. Of the 13 cases of status epilepticus, nine were 
thought to be possibly related to cannabidiol use although 
none of these were associated with reductions in cannabidiol 
or other AEDs.
There was a reduction of 36.5% in the median monthly 
motor seizure frequency when compared to baseline. 39% 
of patients had a reduction by more than 50% in their motor 
seizures and 21% had a reduction by more than 70% in their 
motor seizure frequency.
Comment. This is an open-label trial and caution must be 
exercised in interpreting the results without a control group. 
This study did demonstrate a side effect and efficacy profile 
for cannabidiol which certainly compares with the AEDs 
that would be considered in the group of patients studied 
in this trial and it would seem to suggest that cannabidiol is 
safe to use in this group in the short term.
Devinsky O et al (2016) Lancet Neurol 15(3):270–278.
Trial of cannabidiol for drug‑resistant seizures 
in the Dravet syndrome
This was a double-blind, randomized, placebo controlled 
trial of cannabidiol in children and young adults with Dravet 
syndrome. Dravet syndrome is a severe epileptic encepha-
lopathy with onset typically in the first year of life. Initially 
seizures are fever related, other seizures types follow, includ-
ing generalized tonic–clonic seizures, myoclonic seizures 
and atypical absences, which are typically refractory to treat-
ment. Most children with Dravet syndrome have a significant 
degree of intellectual disability. 75% of cases have mutations 
in the sodium channel gene SCN1A.
Patients were recruited across 23 centers in the USA 
and Europe and were eligible if they had a diagnosis of 
Dravet syndrome, were taking at least one AED, and had 
at least four convulsive seizures in a baseline (4-week) 
period. After the baseline period, there were periods of 
treatment (14 weeks), treatment tapering (10 days) and 
safety follow-up (4 weeks). The primary end point was a 
change in monthly convulsive seizure frequency. Seizures 
were recorded daily by patients or their carers using a voice 
activated recording system. There were also secondary end 
points which included categorical measures of improvement, 
seizure duration, and behavior as well as changes in different 
seizure types.
120 patients were randomized (61 cannabidiol and 59 
placebo) and 108 patients completed the trial (52 in the can-
nabidiol group and 56 in the placebo group). Nine patients 
withdrew from the cannabidiol group (eight because of 
adverse effects) and three patients were withdrawn from 
the placebo group (one because of an adverse event). The 
mean age of the participants was 9.8 years; they had a base-
line median monthly seizure frequency of 120 seizures per 
month and were currently taking a mean of 2.9 AEDs having 
previously tried a mean of 4.6 AEDs.
The median monthly convulsive seizure frequency 
decreased by 38.9% in the cannabidiol group and by 13.3% 
in the placebo group. This was a statistically significant dif-
ference, p = 0.01. There was a similar difference between 
the groups in terms of total number of seizures with the can-
nabidiol group having a reduction in monthly median total 
seizure frequency of 28.6% and the placebo group having a 
reduction in monthly medial total seizure frequency of 9%, 
p = 0.03 for a difference between the groups. There was 
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not a statistically significant difference between the groups 
in terms of the numbers of patients who had at least a 50% 
reduction in seizure frequency (43% in the cannabidiol 
group versus 27% in the placebo group, p = 0.08).
75% of the patients in the cannabidiol group were deemed 
to have adverse effects associated with the drug compared 
with 36% of the patients in the placebo group. Common 
adverse effects in the cannabidiol group included fatigue/
somnolence, diarrhea, decreased appetite, vomiting and 
pyrexia. Twelve patients in the cannabidiol group had a 
raised liver aminotransferase level compared with one 
patient in the placebo group.
Comment. This is a significant paper given that it 
describes a randomized control trial of cannabidiol in epi-
lepsy. It showed that cannabidiol resulted in a greater reduc-
tion in convulsive-seizure frequency than placebo in patients 
with drug-resistant Dravet syndrome and would suggest that 
cannabidiol is a real treatment option in this patient group. 
The results need to be taken in the context that there were 
some adverse drug effects and Dravet’s syndrome is rare and 
genetically homogeneous, and so this approach might not be 
immediately transferable to more common epilepsies.
Devinsky O et al (2017) N Engl J Med. 377(7):699–700.
Conclusion. The evidence is increasing that cannabidiol 
is an effective treatment option for childhood onset severe 
treatment-resistant epilepsies with a tolerable side effect and 
safety profile. Further evidence is needed before cannabidiol 
can be considered in more common or adult onset epilepsies. 
Longer-term safety data for cannabidiol, particularly consid-
ering its effects on the developing brain, are also required.
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